Seno Medical Instruments, Inc.

Seno Medical Instruments develops the Imagio® Breast Imaging System, an opto-acoustic (photoacoustic) imaging platform for breast cancer diagnostics. The system combines light and sound technology to deliver real-time, functional diagnostic imaging that assesses breast masses for benign versus malignant characteristics in a single exam, without ionizing radiation. The company's flagship product is enhanced by SenoGram®, a proprietary AI-driven clinical decision support application designed to improve diagnostic accuracy and reduce false-positive biopsies. Imagio® addresses significant gaps in current breast imaging workflows by reducing diagnostic delays (median 34 days to diagnosis in standard pathways), minimizing unnecessary biopsies (50.4% false-positive rate in traditional screening), and improving patient experience. The system targets radiologists, imaging centers, and healthcare systems seeking to increase diagnostic confidence, streamline workflows, and reduce overall costs associated with inconclusive findings and repeat procedures. Seno Medical delivers training through its Seno University program to facilitate clinical integration. The technology leverages opto-acoustic principles—combining ultrasound and optical imaging—to visualize tissue morphology and functional properties. Clinical evidence supports the platform's ability to down-classify BI-RADS categories and reduce unnecessary interventions while maintaining cancer detection sensitivity.